US Stock Insider Trading | ImmunityBio Discloses 8 Insider Transactions on February 24

K-LinePoet · 2026-03-07T05:55:57+00:00

ImmunityBio disclosed multiple insider transactions on February 24, 2026. Director Simon Barry J. sold 165,000 shares on February 23, involving an amount of $1,691,100. The company focuses on immunotherapy, dedicated to addressing unmet medical needs such as tumors and infectious diseases.

K-LinePoet

2026-03-07 05:55:57

Abstract generation in progress

On February 24, 2026, ImmunityBio (IBRX) disclosed eight insider trading transactions. Director Simon Barry J. sold 165,000 shares on February 23, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 24, 2026	Executive	LAUER REGAN J	February 22, 2026	Sell	1,673	8.70	$14,600
February 24, 2026	Executive	Sachs David C.	February 22, 2026	Sell	20,700	8.70	$179,900
February 24, 2026	Director	Simon Barry J.	February 23, 2026	Sell	165,000	10.25	$1,691,100
February 24, 2026	Director	Adcock Richard	February 22, 2026	Sell	77,600	8.70	$674,800
February 24, 2026	Director	Selecky Christobel	February 23, 2026	Sell	25,000	10.00	$250,000
February 24, 2026	Director	Simon Barry J.	February 20, 2026	Sell	10,000	9.25	$92,500
February 24, 2026	Director	Selecky Christobel	February 23, 2026	Buy	25,000	2.98	$74,500
February 24, 2026	Director	Simon Barry J.	February 22, 2026	Sell	6,026	8.70	$52,240
February 12, 2026	Shareholder with >10%	SOON-SHIONG PATRICK	February 10, 2026	Sell	118,600	6.93	$821,600
February 12, 2026	Director	Adcock Richard	February 10, 2026	Sell	140,000	6.93	$970,500

[Company Profile]

ImmunityBio, Inc. was incorporated on October 7, 2002, under the name ZelleRx Corporation in Illinois, and on January 22, 2010, the company was renamed Conkwest Inc. ImmunityBio is a leading late-stage immunotherapy company that activates innate and adaptive immune systems to address unmet needs in oncology and infectious diseases. The company is a leading manufacturer of ready-to-use natural killer (NK) cell therapies, including memory NK cells, along with a comprehensive platform of antibody-cytokine fusion proteins, albumin-binding immunomodulators, and vaccine carriers. By integrating these NK, macrophage, and T-cell activation platforms, the company believes ImmunityBio is at the forefront of immunotherapy, with late-stage clinical development across multiple tumor types and infectious diseases.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.